Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05419505
Other study ID # EN3835-226
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 15, 2022
Est. completion date June 21, 2023

Study information

Verified date July 2023
Source Endo Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the effect of different doses, strengths (concentrations), diluent additives, depths of injection, and methods of injection on the severity of bruising potentially induced by QWO (collagenase clostridium histolyticum-aaes [CCH-aaes]).


Description:

The study will comprise a Screening Period (28 days), Treatment Period (90 days), and Follow-up Period (90 days). Participants will receive CCH-aaes in different doses, concentrations, diluent additives, depths of injection, and methods of injection in a split buttock arrangement, with the right buttock serving as the control, and the left buttock (investigational side) receiving a study intervention.


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date June 21, 2023
Est. primary completion date January 3, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Key Inclusion Criteria: - Have a body mass index of 18 to <32 kilograms (kg)/meter (m)^2 and intends to maintain stable body weight during the study. - Have both buttocks with moderate or severe cellulite as reported by the investigator using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS). - Have a Hexsel Cellulite Severity Scale (CSS) Total Score of =12. - Has a Fitzpatrick Skin Type of I-IV - Be willing to apply sunscreen to the treatment areas before each exposure to the sun for the duration of participation in the study. - Be willing and able to comply with the requirements of the study. Key Exclusion Criteria: - Has systemic conditions (coagulation disorders, skin pigmentation disorders, malignancy, keloidal scarring, abnormal wound healing) that restricts study participation. - Is pregnant and/or is breast-feeding or plans to become pregnant and/or to breast-feed during the course of the study. - Has any local (in the areas to be treated) conditions (thrombosis, post-thrombosis syndrome, vascular disorder, inflammation, active infection, active cutaneous alteration, tattoo or mole) that restricts study participation. - Requires antiplatelet medication, anticoagulants, or non-steroidal anti-inflammatory drugs during the study. - Any medications, supplements, or foods that have, or have been reported to have anticoagulant effects within 14 days of treatment. - Has received treatment with investigational treatment within 30 days before treatment. - Has used or intends to use any of the local applications, therapies, injections, or procedures for the treatment of cellulite on either buttock that would restrict study participation. - Intends to initiate an intensive sport or exercise program or intensive weight reduction program during the study. - Intends to engage in strenuous activity within 48 hours of study intervention administration. - Has recently tanned or intends to tan (outdoors or indoors) during the study. - Has a history of hypersensitivity or allergy to collagenase or any other excipient of CCH. - Has any condition(s) that, in the investigator's opinion, might indicate the participant to be unsuitable for the study. - Has participated in a previous investigational study of CCH or received any collagenase treatments at any time prior to treatment in this study for the treatment of cellulite of the buttocks. In addition to the applicable aforementioned exclusion criteria, participants enrolling in Cohort 7 will be excluded from study participation if the participant: - Has any of the following medical conditions: 1. history of venous or arterial thromboembolism or current thromboembolic disease. 2. history of or current renal impairment. 3. serum creatinine concentration > 1.4 milligram/deciliter at Screening. - Requires the following concomitant medications during the study and cannot discontinue these medications within the time specified before CCH-aaes treatment: 1. concurrently taking combination hormonal contraceptives. 2. concurrently undergoing hormone replacement therapy. 3. is a current smoker of nicotine or cannabinoids. - Participants in Cohort 7 should avoid smoking (including vaping, nicotine, or marijuana cigarettes) during the study.

Study Design


Related Conditions & MeSH terms

  • Cellulite
  • Edematous Fibrosclerotic Panniculopathy

Intervention

Drug:
CCH-aaes
Administered by subcutaneous injection.
Antifibrinolytic Agent
Self-administered by participants enrolled in Cohort 7.

Locations

Country Name City State
United States Endo Clinical Trial Site #4 Beverly Hills California
United States Endo Clinical Trial Site #3 Chicago Illinois
United States Endo Clinical Trial Site #8 Coral Gables Florida
United States Endo Clinical Trial Site #9 Encinitas California
United States Endo Clinical Trial Site #12 Greenwood Village Colorado
United States Endo Clinical Trial Site #2 Metairie Louisiana
United States Endo Clinical Trial Site #13 Miami Florida
United States Endo Clinical Trial Site #1 Nashville Tennessee
United States Endo Clinical Trial Site #11 New York New York
United States Endo Clinical Trial Site #5 Pflugerville Texas
United States Endo Clinical Trial Site #10 San Diego California
United States Endo Clinical Trial Site #6 Scottsdale Arizona
United States Endo Clinical Trial Site #7 Solana Beach California

Sponsors (1)

Lead Sponsor Collaborator
Endo Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with at Least 1-Level Lower Score for the Left Buttock (Investigational) Versus the Right Buttock (Control), as Assessed by the Investigator Assessment of Bruising Severity Scale (IABSS) After Initial CCH-aaes Injection 3 to 5 days after initial CCH-aaes injection on Day 1 (Cohorts 1 to 7) and Day 22 (Cohort 7 only)
Secondary Number of Participants with at Least 1-Level Lower Score for the Left Buttock (Investigational) Versus the Right Buttock (Control), as Assessed by the IABSS After CCH-aaes Injection Up to Day 64
Secondary Number of Participants with at Least +1 or Higher Score on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) After CCH-aaes Injection From Day 22 through Day 180
Secondary Number of Participants with Treatment-emergent Adverse Events Up to Day 180
Secondary Number of Participants with Injection Site Reactions in the Left Buttock (Investigational) Versus the Right Buttock (Control) Up to Day 180
See also
  Status Clinical Trial Phase
Completed NCT03550157 - Structural Changes of Subcutaneous Tissue by Ultrasonographies in Patients After Treatment With PnKCelulitis® Program
Completed NCT03078647 - Profound Dermal and SubQ Cartridges for the Treatment of Cellulite N/A
Suspended NCT05441917 - Phototherapy and Radiofrecuency for Cellulite N/A
Completed NCT02942160 - EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Phase 2
Active, not recruiting NCT02489994 - Performance of the ePrime System for Cellulite N/A
Completed NCT01209767 - Cryolipolysis and Subcision for Treatment of Cellulite N/A
Completed NCT01702259 - Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks. N/A
Completed NCT04580303 - CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques Phase 2
Completed NCT05358847 - Treatment for Cellulite Appearance N/A
Terminated NCT04209530 - Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women Phase 2
Completed NCT05064761 - Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite N/A
Completed NCT03329989 - Safety and Effectiveness of EN3835 in the Treatment of EFP in Women Phase 2
Completed NCT04170296 - Real World CCH Study in Adult Females With Cellulite Phase 3
Completed NCT04419454 - Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite
Completed NCT05199506 - Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite N/A
Completed NCT05836779 - A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) Phase 2
Completed NCT05026216 - To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite. Phase 4
Completed NCT00399854 - Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring Phase 4
Completed NCT00947414 - Cellulite and Extracorporeal Shock Wave N/A
Completed NCT03981198 - Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite N/A